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Liver and spleen transient elastography
predicts portal hypertension in patients
with chronic liver disease: a prospective
cohort study
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Abstract
Background: To assess correlation between liver or spleen stiffness measurement by transient elastography (TE)
and hepatic venous pressure gradient (HVPG) in patients with chronic liver disease as well find optimal and rule
in/rule out cut-offs for prognosis of clinically significant (CSPH) and severe (SPH) portal hypertension.
Methods: In this prospective study patients with different chronic liver diseases were included. TE was performed
at the same day prior to HVPG measurement. HVPG was measured using catheter tip occlusion technique. Based
on HVPG, patients were categorized into groups of CSPH and SPH. Cut-off values were established by applying
ROC curve analysis.
Results: The study included 107 consecutive patients referred for HVPG measurement or transjugular liver biopsy.
Successful spleen TE was performed in 99 of the patients. Liver and spleen TE strongly correlated with HVPG, r = 0.75
and r = 0.62, respectively. Accuracy to detect CSPH was 88.7 % for liver stiffness of 17.4 kPa and 77.7 % for spleen
stiffness of 47.6 kPa. Accuracy to detect SPH was 83.1 % for liver stiffness of 20.6 kPa and 77.7 % for spleen stiffness of
50.7 kPa. Liver stiffness <11.4 kPa could rule out CSPH with 55.2 % specificity and >21.9 kPa rule in CSPH with 74.4 %
sensitivity. Liver stiffness <12.1 kPa could rule out SPH with 50.0 % specificity and >35 kPa rule in SPH with 58.2 %
sensitivity.
Conclusions: Liver and spleen stiffness correlate with HVPG and could be used to predict CSPH or SPH. Spleen
elastography was not superior to liver elastography in predicting portal hypertension.
Keywords: Transient elastography, Portal hypertension, HVPG, Fibroscan, Non-invasive test, Spleen stiffness, Liver
stiffness
Background
Portal hypertension is a common and important finding in
patients with progressive liver disease of any etiology, lead-
ing to further complications and decreased patient survival
[1, 2]. Direct measurement of portal hypertension is inva-
sive and rarely used in clinical practice due to potential
complications. Measurement of hepatic venous pressure
gradient (HVPG) is established as a primary standard for
evaluation of portal vein pressure, particularly in patients
with hepatic (sinusoidal) portal hypertension. HVPG of less
than 5 mmHg is considered to be normal, while 6–9 mmHg
has been determined as subclinical portal hypertension [2].
It has shown that portal pressure can predict different
outcomes in patients with portal hypertension. HVPG
≥10 mmHg was considered as clinically significant portal
hypertension (CSPH) and was linked to the risk of esopha-
geal varices formation [3], clinical decompensation [4],
development of hepatocellular carcinoma (HCC) [5] or
death after liver resection due to HCC [6]. Hepatic venous
pressure gradient ≥12 mmHg reflected severe portal hyper-
tension (SPH) and was found to be prognostic for acute
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variceal bleeding [7]. HVPG ≥16 mmHg was the predictor
of poor survival in cirrhotic patients [7]. Despite the overall
safety of HVPG measurement, there are some limitations
related to availability of this diagnostic procedure, personal
training, experience, increased health care costs and patient
discomfort. Therefore, different non-invasive tests are
under investigation that potentially could replace HVPG
measurement. Liver stiffness could predict portal pressure
by measuring physical properties of structural changes
emerging in last stages of liver fibrosis; therefore, liver elas-
tography could be potentially accurate tool for stiffness
assessment. Spleen elastography has been investigated as a
tool to reflect dynamic (vascular) component next to struc-
tural part of portal hypertension. Several studies have inves-
tigated diagnostic value of liver elastography; however, the
role of spleen elastography has yet to be established [8–11].
The aim of our study was to assess correlation of liver and
spleen stiffness measured by transient elastography (TE)
with HVPG in patients with chronic liver disease. We also
aimed to find optimal liver and spleen TE values as well as
rule in/rule out values in predicting CSPH and SPH.
Methods
Study design
We performed a single center prospective study in the
Gastroenterology Department at the Hospital of Lithuanian
University of Health Sciences (Kaunas, Lithuania). Patients
with different chronic liver diseases, who were referred for
HVPG measurement or/and transjugular liver biopsy, were
included in the study. As HPVG is an independent prog-
nostic indicator in patients with chronic liver disease [3–7],
patients were included irrespective of their liver biopsy
status. Exclusion criteria was acute hepatitis, multiple focal
liver lesions, cholestatic liver disease, biliary obstruction,
failure to carry out liver transient elastography or patient’s
refusal to participate in this study. Spleen elastography was
performed only if liver elastography was successful. The
study was approved by local Bioethics Committee of
Lithuanian University of Health Sciences (Protocol No.
BE-2-26). All patients have signed an informed consent
form before inclusion.
Investigations
The routine clinical (weight, height), hematological
(complete blood count) and biochemical (international
normalized ratio (INR), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), bilirubin) measure-
ments were performed at the same day prior to HVPG
measurement. Abdominal ultrasonography was performed
to exclude multiple focal liver lesions.
Non-invasive tests
Liver stiffness using FIBROSCAN® (Echosens, Paris, France)
device was measured on the same day before HVPG
measurement. Patients were in fasting state. Procedure was
performed in accordance with manufacturer’s recommen-
dations. Interquartile range/median <30 % and success rate
>60 % was considered as good quality criteria for TE. We
performed 10 successful measurements for each patient.
Liver elastography was unsuccessful in 10 patients (5.9 %),
who were excluded from study.
Assessment of spleen stiffness was performed by the
same methodology used for liver elastography. The quality
criterion (interquartile range/median, success rate and
number of successful measurements) for spleen stiffness
was the same as for liver stiffness. If typical elastography
picture could not be found using FIBROSCAN device,
exact point for spleen stiffness measurement was found
using Toshiba Xario 200 ultrasound device (Toshiba Med-
ical Systems Corporation, Japan).
Hepatic venous pressure gradient
HVPG was measured in fasting state. None of the patients
have received medications affecting portal pressure before
HVPG measurement. The standard criteria for HVPG
measurement was applied [12]. HPVG was measured
using catheter wedge technique by experienced radiologist
using judkins right 6fr catheter (Boston Scientific, USA,
Marlborough). Right hepatic vein was selectively cannu-
lated and catheter position confirmed by vein angiogram.
The occluded position of the catheter was checked by
absence of reflux after the injection of 2 mL of a contrast
medium and appearance of sinusoidogram (Infinity R50,
Drager, Germany). The mean of at least 3 readings was
taken for further analysis. If the difference between the
readings was greater than 1 mmHg, all the previous
recordings were cancelled, and new readings were taken.
Radiologist was blinded to clinical data and liver/spleen
stiffness results.
Statistical analysis
Statistical analysis was performed using SPSS 20.0.
Kolmogorov – Smirnov test was used to check data
normality. For descriptive statistics frequencies, means,
medians and standard deviations were calculated. HVPG
scores were compared with liver and spleen stiffness
expressed in kPa using non-parametric Spearman correl-
ation. Based on HVPG, patients were categorized into
groups with and without CSPH or into those with and
without SPH. Comparisons between patients with and
without CSPH or SPH were made using Mann–Whitney
Test. Areas under the receiver operating characteristic
(AUROC) curve were calculated and points for best speci-
ficity and sensitivity established, positive predictive value
(PPV), negative predictive value (NPV) and accuracy were
calculated. P-values less than 0.05 were considered to be
statistically significant.
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Results
The demographic and clinical characteristics of the pa-
tients are represented in Table 1. Patients mean age was
52.3 years, with similar gender distribution. HCV related
chronic liver disease was predominant and most patients
had compensated liver disease (Child Pugh grade A).
Data of HVPG, spleen and liver elastography are repre-
sented in Table 2. Spearman correlation analysis revealed
that both liver and spleen elastography correlated with
hepatic venous pressure gradient. Strong correlation with
HVPG was found for liver TE (r - 0.75, p < 0.001) and for
spleen TE (r - 0.62, p < 0.001). Comparisons between
patients with and without CSPH or SPH was made using
Mann–Whitney Test. The test revealed that there are
statistically significant differences in liver and spleen stiff-
ness between patients with and without CSPH or with
and without SPH (Figs. 1 and 2).
The AUROC curves for each HVPG category are
presented in Figs. 3 and 4. AUROC curve for HVPG ≥
10 mmHg was 0.949 (p < 0.001) for liver TE and 0.846
(p < 0.001) for spleen TE. AUROC curve for HVPG ≥
12 mmHg was 0.915 (p < 0.001) for liver TE and 0.869
(p < 0.001) for spleen TE. AUROC curve values were
higher for liver elastography than for spleen elastography
and higher for CSPH than for SPH.
Liver and spleen TE cut-off values for different HVPG
categories were established and specificity, sensitivity,
positive predictive value, negative predictive value and
accuracy were calculated (Table 3). To increase the prac-
tical utility of TE, we calculated cut-off point with 100 %
specificity (rule in) or 100 % sensitivity (rule out) of liver
and spleen stiffness for CSPH and SPH. The calculations
revealed that there is no cut-off point with 100 % specifi-
city for spleen stiffness both in HVPG ≥ 10 mmHg and
HVPG ≥ 12 mmHg groups. Only cut-offs with 100 %
sensitivity could be found, however, with little applicabil-
ity. Spleen stiffness of 14.3 kPa had 4.2 % sensitivity for
detecting HVPG ≥ 10 mmHg, while spleen stiffness of
32.6 kPa had 48.6 % sensitivity for HVPG ≥ 12 mmHg.
In contrast to spleen TE data, analysis of liver stiffness
revealed cut-off points with 100 % specificity or sensitiv-
ity in all groups (Table 4).
Discussion
Up to date, several studies that evaluated liver elastogra-
phy for prediction of clinically significant portal hyper-
tension have been published [9–11, 13–17]. In these
studies AUROC curve for prediction of CSPH varies
between 0.81 and 0.94 with optimal cut-offs between
16.8 and 21.95 kPa with sensitivity and specificity of 73.7
- 89.7 % and 73.7 - 82.2 %, respectively [9, 13–15]. Both
AUROC curves and optimal cut-offs observed by other
authors are comparable with our data that show
AUROC of 0.949 and optimal cut-off 17.4 kPa with 88 %
sensitivity and 87.5 % specificity. Nevertheless, applic-
ability of optimal cut-off points is questionable due to
the risk of patient misclassification; therefore, cut-off
points with 100 % sensitivity or specificity could be more
useful to assess portal hypertension non-invasively, espe-
cially in HCC patients referred for surgery for evaluation
of contraindications to perform liver resection. It was
found that liver stiffness >29.0 kPa predicts CSPH with
71.9 % sensitivity and 100 % specificity [10]. Similar
Table 1 Demographic and clinical characteristics of patients




Age, years, mean (±SD) 52.3 (±11.9)
BMI, kg/m2, mean (±SD) 26.7 (±4.2)
Liver disease, n (%)
Hepatitis C 68 (63.6)
Alcoholic liver disease 19 (17.8)
Cryptogenic liver disease 11 (10.3)
Other 9 (8.3)
Successful spleen elastography, n (%) 99 (92.5)
HVPG, n (%)
≥10 mmHg 78 (72.9)
<10 mmHg 29 (27.1)
≥12 mmHg 67 (62.6)
<12 mmHg 40 (37.4)




Platelet count, /Lx109, mean (±SD) 130.2 (±75.5)
ALT, IU/L, mean (±SD) 93.0 (±79.1)
AST, IU/L, mean (±SD) 105.9 (±77.6)
SD standard deviation, BMI body mass index, HVPG hepatic venous pressure
gradient, AST aspartate aminotransaminase, ALT alanine aminotransaminase,
INR international normalized ratio
Table 2 Descriptives of hepatic venous pressure gradient, liver
and spleen transient elastography data
HVPG (mmHg) Spleen TE (kPa) Liver TE (kPa)
N 107 99 107
Std. Error of Mean 0,63 2,01 2,17
Median 14,0 62,7 25,7
Std. Deviation 6,5 20,0 22,4
Range 28 62,9 72,1
Minimum 1 12,1 2,9
Maximum 29 75,0 75,0
HVPG hepatic venous pressure gradient, TE transient elastography
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Fig. 1 The comparison of median liver and spleen stiffness in patients with and without clinically significant portal hypertension (≥10 mmHg);
p-value <0.01 for differences in liver stiffness; p-value <0.01 for differences in spleen stiffness
Fig. 2 Liver and spleen stiffness comparison in patients with and without severe portal hypertension (≥12 mmHg); p-value <0.01 for differences
in liver stiffness; p-value <0.01 for differences in spleen stiffness
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observations were made in other studies where liver
stiffness of >21 kPa in HCV patients predicted CSPH
with sensitivity 42 % and specificity of 100 % [16] or
≥24.2 kPa with sensitivity 52.3 % and specificity 97.1 %
[18]. The rule out cut-off point was found to be <16 kPa
with sensitivity 95.4 % and specificity 68.6 %. Our data
revealed comparable cut-off of 21.9 kPa with sensitivity
of 74.4 % and specificity of 100 %. Combining these
results with the threshold of 11.4 kPa (a measure close
to liver cirrhosis stage) with sensitivity of 100 % and
specificity of 55.2 %, we can determine the “grey zone”
between 11.4 and 21.9 kPa, and correctly classify pa-
tients outside of it. This strategy could be implemented
into decision making for HCC patients, were HVPG ≥
10 mmHg predicts higher mortality and liver dysfunc-
tion after liver resection. This group of patients could
avoid unnecessary HVPG measurement if TE measure-
ment is outside the “grey zone”.
Few studies investigated liver TE in SPH, where
AUROC curve was found to be between 0.79 and 0.92
Fig. 3 AUROC curves of liver and spleen transient elastography for clinically significant portal hypertension (≥10 mmHg)
Fig. 4 AUROC curves of liver and spleen transient elastography for severe portal hypertension (≥12 mmHg)
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[13, 15, 19, 20]. The optimal cut-offs to predict SPH
varied between 17.6 and 24.2 kPa with sensitivity and
specificity of 82.9 – 94 % and 66.6 – 81 %, respectively
[13, 15, 19, 20]. Our study revealed comparable results
with optimal cut-off 20.6 kPa. Considering marginal cut-
offs, our study revealed that rule out cut-off of 12.1 kPa
had 50 % specificity, though it was almost the same as in
CSPH group. Rule in cut-off point of 35.0 kPa had sensi-
tivity of 58.2 % and it is further than CSPH cut-off.
Studies analyzing correlation of spleen stiffness mea-
sured by transient elastography with HVPG are still
scarce. Colechia et al. found strong correlation between
spleen stiffness and HVPG (r – 0.88) [18]. The marginal
cut-off points were calculated to rule in or rule out
CSPH or SPH. For CSPH cut-off 40.0 kPa had sensitivity
of 98.5 % and specificity of 74.3 % and cut-off 52.8 kPa
76.9 % and 97.1 %, respectively. For SPH cut-off 41.3
kPa had sensitivity of 98.1 % and specificity of 67.4 %
and cut-off 55.0 kPa - 72.2 % and 97.8 %, respectively.
Our study did not show clinically useful rule in and rule
out points obtained by measurement of spleen stiffness,
because of wide scatter and overlap of spleen elastogra-
phy in CSPH and SPH groups. In comparison, the cut-
off 40 kPa in our cohort had sensitivity of 85 % and
specificity of 70 % and cut-off 53.0 kPa 69.3 % and
83.3 %, respectively, for CSPH. Another study found no
significant differences in spleen stiffness measured by TE
between groups analyzing CSPH or SPH [8], although
the study was underpowered including only 35 patients
with just three patients without CSPH.
Our data show that liver and spleen elastography
correlate well with HVPG, however liver stiffness has
better correlation coefficient and AUROC than spleen
elastography. We expected that spleen elastography
might be more accurate than liver elastography for evalu-
ation of HVPG subgroups because it reflects dynamic
component of portal hypertension. Insufficient accuracy
of spleen TE could be partially explained by influence of
various shunts, arising during progression of portal hyper-
tension. Taking into account other drawbacks of spleen
elastography such as decreased success of spleen TE per-
formance, missing cut-off points with 100 % specificity or
sensitivity and less standardized procedure, it appears to
suggest little benefit in clinical practice and no significant
advantage over liver elastography. The wide variation of
liver transaminases in our patients cohort could lead to
higher transient elastography values and consequently to
higher cut-off, as noted in different studies analyzing
correlation of TE with liver fibrosis [21]. However, diag-
nostic accuracy of TE for cirrhosis stage is considered
reliable and the influence of inflammation is less pro-
nounced [21, 22]. Although liver biopsy was performed
just in half of our patients, most of them had cirrhosis or
pre-cirrhosis stage and all patients without biopsy where
diagnosed as having cirrhosis based on laboratory, radio-
logic and clinical features. Therefore, we think that liver
transaminases did not introduce significant bias into our
data. To decrease the influence of inflammation to our
data, we excluded all patients with acute and acute on
chronic hepatitis. In our study most of the patients
belonged to Child A class. Inclusion of more advanced
stages of liver cirrhosis in such studies is often compli-
cated by the presence of ascites which reflects one of the
limitations of TE. The benefit of spleen stiffness measure-
ment for evaluation of prognosis in patients with portal
hypertension still has to be determined in further studies.
The limitations of TE potentially could be resolved using
other elastography types such as Acoustic Radiation Force
Impulse imaging or Shear Wave Elastography. Further
studies have to evaluate whether spleen elastography
could be superior to liver elastography with these new
elastography techniques for non-invasive estimation of
portal hypertension [23].
Conclusions
Our study revealed that both liver and spleen stiffness
measured by transient elastography correlate with hepatic
Table 3 Optimal cut-offs of liver and spleen stiffness for prediction of clinically significant (≥10 mmHg) and severe (≥12 mmHg)
portal hypertension
HVPG Method Cut-off, kPa Sensitivity, % Specificity, % PPV, % NPV, % Accuracy, %
≥10 mmHg Liver TE 17.4 88.0 87.5 95.8 74.2 88.7
Spleen TE 47.6 77.3 79.2 92.0 52.7 77.7
≥12 mmHg Liver TE 20.6 82.8 80.0 88.8 0.75 83.1
Spleen TE 50.7 78.1 77.1 86.2 65.8 77.7
HVPG hepatic venous pressure gradient, PPV positive predictive value, NPV negative predictive value
Table 4 Rule in and rule out cut-offs of liver stiffness for prediction
of clinically significant (≥10 mmHg) and severe (≥12 mmHg) portal
hypertension
HVPG Method Cut-off, kPa Sensitivity, % Specificity, %
≥10 mmHg Liver TE 11.4 100 55.2
21.9 74.4 100
≥12 mmHg Liver TE 12.1 100 50.0
35.0 58.2 100
HVPG hepatic venous pressure gradient, TE transient elastography
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venous pressure gradient. However, spleen elastography
has no advantage in comparison to standard liver elasto-
graphy for prediction of clinically significant or severe por-
tal hypertension. Liver stiffness <11.4 kPa could rule out
and >21.9 kPa rule in clinically significant portal hyperten-
sion. Liver stiffness <12.1 kPa could rule out and >35 kPa
rule in severe portal hypertension.
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